Reply: Strong Bias Toward Performing Percutaneous Coronary Intervention in Patients With Chronic Total Occlusion Despite Lack of Important Benefit at a Very High Cost and Risk to the Patient

Peter Tajti; M. Nicholas Burke; Dimitri Karmpaliotis; Khaldoon Alaswad; Gerald S. Werner; Lorenzo Azzalini; Mauro Carlino; Mitul Patel; Kambis Mashayekhi; Mohaned Egred; Oleg Krestyaninov; Dmitrii Khelimskii; William J. Nicholson; Imre Ungi; Alfredo R. Galassi; Subhash Banerjee; Emmanouil S. Brilakis

doi:10.1016/j.jcin.2018.05.015

Reply: Strong Bias Toward Performing Percutaneous Coronary Intervention in Patients With Chronic Total Occlusion Despite Lack of Important Benefit at a Very High Cost and Risk to the Patient

Peter Tajti
, M. Nicholas Burke
, Dimitri Karmpaliotis
, Khaldoon Alaswad
, Gerald S. Werner
, Lorenzo Azzalini
, Mauro Carlino
, Mitul Patel
, Kambis Mashayekhi
, Mohaned Egred
, Oleg Krestyaninov
, Dmitrii Khelimskii
, William J. Nicholson
, Imre Ungi
, Alfredo R. Galassi
, Subhash Banerjee
, Emmanouil S. Brilakis

Icahn School of Medicine at Mount Sinai

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	1541-1542
Number of pages	2
Journal	JACC: Cardiovascular Interventions
Volume	11
Issue number	15
DOIs	https://doi.org/10.1016/j.jcin.2018.05.015
State	Published - 13 Aug 2018

Access to Document

10.1016/j.jcin.2018.05.015

Cite this

Tajti, P., Burke, M. N., Karmpaliotis, D., Alaswad, K., Werner, G. S., Azzalini, L., Carlino, M., Patel, M., Mashayekhi, K., Egred, M., Krestyaninov, O., Khelimskii, D., Nicholson, W. J., Ungi, I., Galassi, A. R., Banerjee, S., & Brilakis, E. S. (2018). Reply: Strong Bias Toward Performing Percutaneous Coronary Intervention in Patients With Chronic Total Occlusion Despite Lack of Important Benefit at a Very High Cost and Risk to the Patient. JACC: Cardiovascular Interventions, 11(15), 1541-1542. https://doi.org/10.1016/j.jcin.2018.05.015

@article{0cd127fa85fb48c894ba8e396b4e909d,

title = "Reply: Strong Bias Toward Performing Percutaneous Coronary Intervention in Patients With Chronic Total Occlusion Despite Lack of Important Benefit at a Very High Cost and Risk to the Patient",

author = "Peter Tajti and Burke, \{M. Nicholas\} and Dimitri Karmpaliotis and Khaldoon Alaswad and Werner, \{Gerald S.\} and Lorenzo Azzalini and Mauro Carlino and Mitul Patel and Kambis Mashayekhi and Mohaned Egred and Oleg Krestyaninov and Dmitrii Khelimskii and Nicholson, \{William J.\} and Imre Ungi and Galassi, \{Alfredo R.\} and Subhash Banerjee and Brilakis, \{Emmanouil S.\}",

note = "Funding Information: Please note: Dr. Burke has received consulting and speaker honoraria from Abbott Vascular and Boston Scientific. Dr. Karmpaliotis has received speaker honoraria from Abbott Vascular, Medtronic, Boston Scientific, and Vascular Solutions. Dr. Alaswad has received consulting fees from Terumo and Boston Scientific; and has been an (unpaid) consultant for Abbott Laboratories. Dr. Werner has received speaker honoraria for Asahi Intecc, Abbott Vascular, Biosensors, and Terumo; and has been the principal investigator of a randomized trial on the benefit of CTO PCI versus medical therapy conducted by the EURO CTO Club sponsored by Asahi Intecc and Biosensors. Dr. Patel has received consulting honoraria from Abbott Vascular. Dr. Mashayekhi has received honoraria from Asahi Intecc. Dr. Nicholson has been a proctor or served on the Speakers Bureau/Advisory Board of Abbott Vascular, Boston Scientific, and Asahi Intecc; and holds intellectual property in Vascular Solutions. Dr. Banerjee has received research grants from Gilead and The Medicines Company; received consultant/speaker honoraria from Covidien and Medtronic; holds intellectual property in HygeiaTel; and his spouse has ownership in DCARE Global. Dr. Brilakis has received consulting/speaker honoraria from Abbott Vascular, ACIST Medical Systems, Amgen, Asahi Intecc, CSI, Elsevier, GE Healthcare, Medicure, Medtronic, and Nitiloop; received research support from Boston Scientific and Osprey; served on the board of directors of Cardiovascular Innovations Foundation; and served on the board of trustees of Society of Cardiovascular Angiography and Interventions. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. ",

year = "2018",

month = aug,

day = "13",

doi = "10.1016/j.jcin.2018.05.015",

language = "English",

volume = "11",

pages = "1541--1542",

journal = "JACC: Cardiovascular Interventions",

issn = "1936-8798",

publisher = "Elsevier Inc.",

number = "15",

}

Tajti, P, Burke, MN, Karmpaliotis, D, Alaswad, K, Werner, GS, Azzalini, L, Carlino, M, Patel, M, Mashayekhi, K, Egred, M, Krestyaninov, O, Khelimskii, D, Nicholson, WJ, Ungi, I, Galassi, AR, Banerjee, S & Brilakis, ES 2018, 'Reply: Strong Bias Toward Performing Percutaneous Coronary Intervention in Patients With Chronic Total Occlusion Despite Lack of Important Benefit at a Very High Cost and Risk to the Patient', JACC: Cardiovascular Interventions, vol. 11, no. 15, pp. 1541-1542. https://doi.org/10.1016/j.jcin.2018.05.015

Reply: Strong Bias Toward Performing Percutaneous Coronary Intervention in Patients With Chronic Total Occlusion Despite Lack of Important Benefit at a Very High Cost and Risk to the Patient. / Tajti, Peter; Burke, M. Nicholas; Karmpaliotis, Dimitri et al.
In: JACC: Cardiovascular Interventions, Vol. 11, No. 15, 13.08.2018, p. 1541-1542.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Reply

T2 - Strong Bias Toward Performing Percutaneous Coronary Intervention in Patients With Chronic Total Occlusion Despite Lack of Important Benefit at a Very High Cost and Risk to the Patient

AU - Tajti, Peter

AU - Burke, M. Nicholas

AU - Karmpaliotis, Dimitri

AU - Alaswad, Khaldoon

AU - Werner, Gerald S.

AU - Azzalini, Lorenzo

AU - Carlino, Mauro

AU - Patel, Mitul

AU - Mashayekhi, Kambis

AU - Egred, Mohaned

AU - Krestyaninov, Oleg

AU - Khelimskii, Dmitrii

AU - Nicholson, William J.

AU - Ungi, Imre

AU - Galassi, Alfredo R.

AU - Banerjee, Subhash

AU - Brilakis, Emmanouil S.

N1 - Funding Information: Please note: Dr. Burke has received consulting and speaker honoraria from Abbott Vascular and Boston Scientific. Dr. Karmpaliotis has received speaker honoraria from Abbott Vascular, Medtronic, Boston Scientific, and Vascular Solutions. Dr. Alaswad has received consulting fees from Terumo and Boston Scientific; and has been an (unpaid) consultant for Abbott Laboratories. Dr. Werner has received speaker honoraria for Asahi Intecc, Abbott Vascular, Biosensors, and Terumo; and has been the principal investigator of a randomized trial on the benefit of CTO PCI versus medical therapy conducted by the EURO CTO Club sponsored by Asahi Intecc and Biosensors. Dr. Patel has received consulting honoraria from Abbott Vascular. Dr. Mashayekhi has received honoraria from Asahi Intecc. Dr. Nicholson has been a proctor or served on the Speakers Bureau/Advisory Board of Abbott Vascular, Boston Scientific, and Asahi Intecc; and holds intellectual property in Vascular Solutions. Dr. Banerjee has received research grants from Gilead and The Medicines Company; received consultant/speaker honoraria from Covidien and Medtronic; holds intellectual property in HygeiaTel; and his spouse has ownership in DCARE Global. Dr. Brilakis has received consulting/speaker honoraria from Abbott Vascular, ACIST Medical Systems, Amgen, Asahi Intecc, CSI, Elsevier, GE Healthcare, Medicure, Medtronic, and Nitiloop; received research support from Boston Scientific and Osprey; served on the board of directors of Cardiovascular Innovations Foundation; and served on the board of trustees of Society of Cardiovascular Angiography and Interventions. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2018/8/13

Y1 - 2018/8/13

UR - https://www.scopus.com/pages/publications/85050669831

U2 - 10.1016/j.jcin.2018.05.015

DO - 10.1016/j.jcin.2018.05.015

M3 - Letter

C2 - 30093064

AN - SCOPUS:85050669831

SN - 1936-8798

VL - 11

SP - 1541

EP - 1542

JO - JACC: Cardiovascular Interventions

JF - JACC: Cardiovascular Interventions

IS - 15

ER -